Insmed Incorporated - Common Stock (INSM)

Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls.

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome Powell th

Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.

Financial giants have made a conspicuous bearish move on Insmed. Our analysis of options history for Insmed (NASDAQ: INSM) revealed 29 unusual trades.

The company sells Tyvaso, a treatment for lung diseases. On Tuesday, Tyvaso showed promise, again, in a chronic condition.

Millennium Management's Q2 2025 13F reveals big bets on crypto (IBIT, PLTR) & healthcare (EW, INSM), with tech rebalancing. Read key changes!

The after-hours surge came as management pointed to hospital market share gains from a distracted competitor and rising bronchiectasis awareness following Insmed’s FDA-approved drug launch.

Insmed gains FDA approval for Brinsupri in bronchiectasis, while analysts see multi-billion sales potential from its expanding pipeline through 2035

These 10 large-cap stocks gained this week, some due to positive news such as media rights deals or FDA approvals.